BR9909345A - Pirrolo [1,2-a] pirazina inibidor de spla2 - Google Patents

Pirrolo [1,2-a] pirazina inibidor de spla2

Info

Publication number
BR9909345A
BR9909345A BR9909345-6A BR9909345A BR9909345A BR 9909345 A BR9909345 A BR 9909345A BR 9909345 A BR9909345 A BR 9909345A BR 9909345 A BR9909345 A BR 9909345A
Authority
BR
Brazil
Prior art keywords
pyrazine
pyrrole
interfering
spla
spla2 inhibitor
Prior art date
Application number
BR9909345-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Mitsuaki Ohtani
Masahiro Fuji
Tetsuo Okada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR9909345A publication Critical patent/BR9909345A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9909345-6A 1998-03-31 1999-03-31 Pirrolo [1,2-a] pirazina inibidor de spla2 BR9909345A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (1)

Publication Number Publication Date
BR9909345A true BR9909345A (pt) 2000-12-12

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909345-6A BR9909345A (pt) 1998-03-31 1999-03-31 Pirrolo [1,2-a] pirazina inibidor de spla2

Country Status (11)

Country Link
US (1) US6407104B1 (cg-RX-API-DMAC7.html)
EP (1) EP1066290A1 (cg-RX-API-DMAC7.html)
JP (1) JP4412521B2 (cg-RX-API-DMAC7.html)
KR (1) KR20010042307A (cg-RX-API-DMAC7.html)
CN (1) CN1303384A (cg-RX-API-DMAC7.html)
AU (1) AU3054399A (cg-RX-API-DMAC7.html)
BR (1) BR9909345A (cg-RX-API-DMAC7.html)
CA (1) CA2326522A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0102981A3 (cg-RX-API-DMAC7.html)
NO (1) NO20004881L (cg-RX-API-DMAC7.html)
WO (1) WO1999051605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931963D1 (de) * 1998-10-14 2006-07-27 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
JP4636521B2 (ja) 1999-07-19 2011-02-23 塩野義製薬株式会社 sPLA2阻害作用を有する三環系化合物
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
WO2001036420A1 (en) * 1999-11-15 2001-05-25 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an spla2- inhibiting effect
WO2002000256A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
JP2004505982A (ja) * 2000-08-04 2004-02-26 イーライ・リリー・アンド・カンパニー 新規なsPLA2インヒビター
TWI314457B (cg-RX-API-DMAC7.html) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (de) * 2001-11-13 2003-05-28 Morphochem Ag Serin Protease Inhibitoren
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN105622616A (zh) * 2016-02-25 2016-06-01 上海雅本化学有限公司 一种4-氯吡咯并嘧啶的制备方法
US20250129010A1 (en) * 2021-09-17 2025-04-24 Mitsui Chemicals, Inc. Method for producing (meth)acrylamide compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
EP1950200B1 (en) 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
IL124871A (en) 1995-12-13 2002-04-21 Lilly Co Eli Naphthyl glyoxamides and medicinal preparations containing them, as inhibitors of sPLA2
DE69614232T2 (de) 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Also Published As

Publication number Publication date
US6407104B1 (en) 2002-06-18
HUP0102981A3 (en) 2002-10-28
CN1303384A (zh) 2001-07-11
EP1066290A1 (en) 2001-01-10
JP2002530268A (ja) 2002-09-17
AU3054399A (en) 1999-10-25
KR20010042307A (ko) 2001-05-25
CA2326522A1 (en) 1999-10-14
HUP0102981A2 (hu) 2002-01-28
NO20004881D0 (no) 2000-09-28
WO1999051605A1 (en) 1999-10-14
NO20004881L (no) 2000-11-28
JP4412521B2 (ja) 2010-02-10

Similar Documents

Publication Publication Date Title
BR9911048A (pt) Inibidor de spla2 de pirrolo[1,2-b]piridazina
NO20004881L (no) Pyrrolo[1,2-a]pyrazin sPLA2 inhibitor
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
DE69521500D1 (de) Phosphorsäurediester-derivate
BR9813848A (pt) Composto heterocìclico fundido substituìdo, uso do mesmo, e, composição farmacêutica.
CO4970702A1 (es) Quinolonas antimicrobianas, sus composiciones y sus usos
DE69919397D1 (de) Thrombin-inhibitoren
DK250386A (da) Fremgangsmaade til fremstilling af heterocycliske forbindelser
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
YU16899A (sh) Aralkil i aralkiliden heterociklicni laktami i imidi
ES2001519A6 (es) Procedimiento para preparar compuestos aromaticos triciclicos y su empleo en composiciones farmaceuticas.
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
DK1106612T3 (da) Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
NZ507564A (en) 4-substituted carbazole or tetrahydrocarbazole derivatives
DE60332350D1 (de) Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten
MX9100227A (es) Derivados de cefalosporina y procedimiento para su preparacion.
ATE61347T1 (de) Zytoprotektive derivate zur anwendung bei ischaemischen erkrankungen, ihre herstellung und sie enthaltende zusammensetzungen.
TW200624541A (en) Flameproof rubber-reinforced styrenic resin composition
YU19099A (sh) Supstituisani tricikli
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
ES8606236A1 (es) Un procedimiento para la preparacion de un compuesto de calixareno.
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
MX170732B (es) Composicion de derivados de succinimida y su uso
DE69924887D1 (de) Antibakterielle mittel
ATE229538T1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O,6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.